E!7178 BROAD-ICI Red Glead Discovery
| Reference number | |
| Coordinator | RG Discovery AB |
| Funding from Vinnova | SEK 2 413 918 |
| Project duration | February 2025 - January 2028 |
| Status | Ongoing |
| Venture | Eurostars |
Purpose and goal
Cellmover and RG Discovery will develop a broad immune check-point inhibitor (ICI) to widen the utility of cancer immunotherapy compared to today. Even though the available ICI’s have revolutionized the treatment of certain cancer-types, there are limitations, e. g. only three of the more than 50 receptors involved in the downregulation of the immune system can be targeted. An ICI capable of inhibiting additional, as well as multiple receptors, would allow the treatment of new types of cancer.
Expected effects and result
A successful project is expected to result in a new type of ICI with a broader receptor-binding profile, that can be evaluated in phase I clinical trials. The project will also result in a better understanding about how a nanobody, or a synthetic peptide can be used within immune therapy.
Planned approach and implementation
Through a close collaboration between CMO and RGD, and by using an iterative stepwise process, the project will increase its knowledge base to allow design of improved ICI’s. This process will utilize expertise already available at RGD, such as computer- and structure-based design, NMR-studies and synthesis of peptides. CMO will coordinate the activities, assess the ICI’s in relevant assays and build new knowledge for the design of nanobodies and peptides for intracellular delivery.